Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock

MPM BioVentures 2014, L.P., a 10% owner of Entrada Therapeutics, has sold approximately $1.91 million worth of the company's common stock over three trading days in early September 2026. The transactions involved selling 38,500 shares at a weighted average price of $7.11 per share, followed by an additional 192,500 shares at $7.41 per share, and finally 28,837 shares at $7.13 per share.

As a result, MPM BioVentures now owns 3,885,115 shares of Entrada Therapeutics, bringing their beneficial ownership in the company to that level. The recent sales come amid operational challenges for Entrada, including rapid cash burn and an anticipated revenue decline this year, which has led to a 31% year-to-date decline in the stock price, currently trading at $7.11.

Despite this, InvestingPro analysis suggests that the shares remain undervalued with a Fair Value of $7.91.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.